Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Autor: Lugtenburg, Pieternella J, Zijlstra, Josee M, Doorduijn, Jeanette K, Böhmer, Lara H, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, van der Burg-de Graauw, Nicole C, Schouten, Harry C, Bilgin, Yavuz M, Kersten, Marie-Jose, Koene, Harry R, Herbers, Alexandra H E, de Jong, Daphne, Hijmering, Nathalie, Lam, King H, Chiţu, Dana, Brouwer, Rolf E, van Imhoff, Gustaaf W

Publikováno v: British Journal of Haematology, 187(3), 347-355. Wiley
British Journal of Haematology, 187(3), 347-355. Wiley-Blackwell Publishing Ltd

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3a5a9275e83857f2214d979536b839da
https://cris.maastrichtuniversity.nl/en/publications/adc39e10-7463-48ff-b6dd-4f5df887f6da

Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Autor: Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W.

Publikováno v: Lugtenburg, P J, Zijlstra, J M, Doorduijn, J K, Böhmer, L H, Hoogendoorn, M, Berenschot, H W, Beeker, A, van der Burg-de Graauw, N C, Schouten, H C, Bilgin, Y M, Kersten, M-J, Koene, H R, Herbers, A H E, de Jong, D, Hijmering, N, Lam, K H, Chiţu, D, Brouwer, R E, van Imhoff, G W & the Dutch HOVON group 2019, ' Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study ', British Journal of Haematology, vol. 187, no. 3, pp. 347-355 . https://doi.org/10.1111/bjh.16087
British Journal of Haematology, 187(3), 347-355. Wiley-Blackwell
British journal of haematology, 187(3), 347-355. Wiley-Blackwell

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::67d0628a8b671ff7539f87f2ea5264be
https://research.vumc.nl/en/publications/83f5a36e-71a9-4023-a0a7-7b829de79611

Rituximab‐PECC induction followed by ⁹⁰Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Autor: Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg‐de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie‐Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W.

Publikováno v: British Journal of Haematology; Nov2019, Vol. 187 Issue 3, p347-355, 9p, 1 Diagram, 2 Charts, 1 Graph

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SARS-CoV-2-Induced Multisystem Inflammatory Syndrome in a Young Adult: Case Report.

Autor: Bulut H; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Herbers AHE; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Hageman IMG; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Netten PM; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., de Jonge HJM; Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Joustra R; Department of Cardiology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., van de Veerdonk FL; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., de Jager CPC; Department of Intensive Care Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.

Publikováno v: SN comprehensive clinical medicine [SN Compr Clin Med] 2021; Vol. 3 (8), pp. 1773-1779. Date of Electronic Publication: 2021 Jun 20.